Metabolon Announces Findings from Two Major Diabetes Outcomes Studies
Complete the form below to unlock access to ALL audio articles.
Metabolon, Inc. announces results from two large-cohort studies evaluating the clinical utility of Quantose, the company’s blood test for prediabetes.
The performance of Quantose was measured among 3,841 participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) and Botnia Prospective Study cohorts. Notably, among initially healthy participants in the RISC study with 3-year follow-up data:
• Quantose biomarkers α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) independently and significantly predicted worsening glycemic control, and;
• Quantose outperformed traditional risk measures such as fasting insulin, fasting glucose, BMI, and HOMA-IR in predicting insulin resistance and progression to impaired glucose tolerance.
In the Botnia Prospective Study with 9.5 year follow-up data:
• Quantose biomarkers were found to predict incident type 2 diabetes independent of familial diabetes, sex, age, BMI, and fasting glucose.
These findings were published in two recent articles:
“Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance”,Diabetes; Ferrannini, Gall, et.al.; 2013; 62(5): 1730.
“A Novel Fasting Blood Test for Insulin Resistance and Prediabetes” Journal of Diabetes Science and Technology; Ferrannini, Cobb, et.al.; 2013; 7(1): 100.
The Quantose test reflects insulin resistance and detects progression to prediabetes and diabetes earlier than traditional glycemic measures such a hemoglobin A1C. The test is particularly useful in identifying prediabetic patients at greatest risk of disease progression and for whom drug, or other interventional therapy, may be appropriate. Diagnostic assessment with the Quantose test is well-aligned with the American Diabetes Association guidelines which recommend that physicians consider pharmaceutical intervention in high-risk prediabetics.
Beyond its immediate impact on the treatment of prediabetes, Quantose offers convincing evidence of the maturation of the field of metabolomics -- and of the potential influence the discovery of novel metabolomic biomarkers will have on personalized medicine. Metabolon is committed to utilizing its systematic metabolomics discovery approach to develop diagnostics in the areas of metabolic, cancer and cardiovascular disease and provide biomarker research services by employing their high-throughput, advanced metabolomics platform.
“These studies are clear affirmation of Quantose value to predict early those individuals at risk for eventual onset of Type 2 diabetes which may provide clinicians the opportunity for treatment interventions that may reverse the prediabetic state,” Eric Button, Senior Vice President of Diagnostics, Metabolon commented.
